7.2 Bone Remodelling and the RANK/RANKL/OPG Axis

2. Cellular Kinetics of Bone Remodelling: The Basic Multicellular Unit (BMU)

Bone is continuously renewed through targeted coupling of osteoclastic bone resorption and osteoblastic bone formation executed by the Basic Multicellular Unit (BMU). Alveolar bone exhibits one of the highest turnover rates in the human skeleton due to constant masticatory loading and occlusal demands.

          ┌───────────────────────────────────────────────────────────┐
          ▼                                                           │
1. ACTIVATION ──▶ 2. RESORPTION ──▶ 3. REVERSAL ──▶ 4. FORMATION ──▶ 5. QUIESCENCE
Osteoclast        Osteoclast seals  Macrophages     Osteoblasts      Osteocytes
precursors        Howship's lacuna  clean debris;   deposit osteoid; entomb in bone;
recruited         Pumps H+ &        Cement line     Mineralize via   Inhibit Wnt via
(RANKL binding)   Cathepsin K       deposited       ALP vesicles     Sclerostin

Bone Cell Lineages and Biological Mechanics

• Osteoblasts:
  • Derived from local mesenchymal stem cells (MSCs) under the master transcriptional control of Runx2 (Cbfa1) and Osterix (Osx).
  • Cuboidal, mononucleated cells that line bone-forming surfaces. Highly active osteoblasts possess abundant rough endoplasmic reticulum and prominent Golgi apparatuses to synthesize and secrete the organic bone matrix (osteoid).
  • Osteoid Composition: 90% Type I collagen and 10% non-collagenous proteins (osteocalcin, osteopontin, bone sialoprotein).
  • Mineralization Function: Osteoblasts express high levels of membrane-bound Tissue Non-Specific Alkaline Phosphatase (TNAP / ALP) on their external membranes. ALP hydrolyses inorganic pyrophosphate (PPᵢ, a potent natural inhibitor of calcification) into free inorganic phosphate (Pᵢ). This elevates local phosphate concentrations, driving the nucleation and precipitation of calcium and phosphate into hydroxyapatite crystals [Ca₁₀(PO₄)₆(OH)₂] within extracellular matrix vesicles.
• Osteocytes:
  • Mature terminal cells derived from osteoblasts that become engulfed within the newly mineralized matrix, residing inside microscopic cavities termed lacunae.
  • Represent >90–95% of all bone cells in the adult skeleton, with an exceptional lifespan spanning decades.
  • Maintain an extensive three-dimensional syncytial network via dendritic cytoplasmic processes traversing radiating canaliculi. Processes communicate directly with adjacent osteocytes and surface lining cells through connexin 43 (Cx43) gap junctions.
  • Mechanotransduction: Osteocytes are the master mechanosensory cells of bone. Interstitial fluid flow through the canalicular network under mechanical shear stress generates fluid shear stress across osteocyte membranes. This triggers intracellular calcium influx, nitric oxide (NO) generation, and prostaglandin E₂ (PGE₂) release, instructing osteoblasts to deposit new bone along stress lines (Wolff's Law).
  • Sclerostin Regulation: When bone is unloaded or disused (e.g., following tooth extraction), osteocytes secrete sclerostin (encoded by the SOST gene). Sclerostin binds to LRP5/6 receptors on osteoblasts, inhibiting canonical Wnt/β-catenin signalling and halting bone formation. Mechanical loading downregulates sclerostin, releasing Wnt inhibition and stimulating bone accretion.
• Osteoclasts:
  • Derived from haematopoietic stem cells of the monocyte/macrophage lineage under the dual stimulation of Macrophage Colony-Stimulating Factor (M-CSF) and RANKL.
  • Terminally differentiated, multinucleated giant cells (containing 4 to 20 nuclei) expressing high levels of Tartrate-Resistant Acid Phosphatase (TRAP).
  • Resorption Cycle:
    1. Attachment and Polarization: Osteoclasts attach to mineralized bone surfaces via αvβ3 integrins binding to Arg-Gly-Asp (RGD) motifs of osteopontin and bone sialoprotein. This forms a specialized, actin-rich circumferential sealing zone (clear zone), isolating the sub-osteoclastic microenvironment from the extracellular fluid.
    2. Ruffled Border Formation: Massive fusion of secretory lysosomes with the enclosed apical membrane creates the ruffled border—a highly folded membrane surface.
    3. Acidification (Inorganic Dissolution): Cytoplasmic carbonic anhydrase II (CA II) generates protons (H⁺). The osteoclast actively pumps H⁺ across the ruffled border into the sealed resorption pit (Howship's lacuna) using electrogenic vacuolar-type H⁺-ATPase (V-ATPase) pumps, driving the lacunar pH down to ~4.5. This intense acidity dissolves the inorganic hydroxyapatite crystals, liberating Ca²⁺ and PO₄³⁻.
    4. Enzymatic Degradation (Organic Cleavage): The osteoclast exocytoses lysosomal Cathepsin K and Matrix Metalloproteinases (MMP-9) into the acidic lacuna. Cathepsin K cleaves the telopeptide and triple-helix domains of demineralized Type I collagen, leaving behind a scooped-out Howship's lacuna.

The Remodelling Sequence (BMU Lifecycle)

1. Activation Phase (Days): Physical microdamage, mechanical disuse, or inflammatory cytokines (IL-1, TNF-α) trigger osteocyte apoptosis or signal lining cells to withdraw, exposing mineralized bone. Osteoclast precursors are recruited from blood vessels.
2. Resorption Phase (2 to 4 Weeks): Multinucleated osteoclasts excavate Howship's lacunae to a programmed depth.
3. Reversal Phase (1 to 2 Weeks): Osteoclasts detach and undergo apoptosis. Mononuclear macrophage-like reversal cells debride remaining organic matrix debris and deposit a proteoglycan-rich, non-collagenous adhesive layer known as the cement line (reversal line), which anchors newly formed bone to the old bone bed.
4. Formation Phase (3 to 4 Months): Differentiated osteoblasts migrate into the lacuna, laying down unmineralized osteoid in organized lamellae at ~1 μm/day.
5. Mineralization Phase: Primary mineralization achieves ~70% mineral content within days; secondary mineralization slowly completes over months.
6. Quiescence: Osteoblasts either flatten to become inactive bone lining cells, undergo apoptosis, or become entombed as osteocytes.

---

3. The Molecular RANK/RANKL/OPG Axis in Health and Disease

The coupling of bone resorption and formation is orchestrated at the molecular level by three members of the tumour necrosis factor (TNF) and TNF-receptor superfamilies:

                       ┌────────────────────────────┐
                       │     Osteoblast / Stroma    │
                       └──────────────┬─────────────┘
                                      │ Secretes
                   ┌──────────────────┴──────────────────┐
                   ▼                                     ▼
               [ RANKL ]                             [ OPG ] (Soluble Decoy)
                   │                                     │
                   │   Interception / Neutralization     │
                   │ ◀───────────────────────────────────┘
                   │ (Prevents RANK activation)
                   ▼
                [ RANK ] (Transmembrane Receptor)
                   │
         [ Osteoclast Precursor ]
                   │
                   ▼ (Recruits TRAF6)
     Activates NF-κB, MAPKs & NFATc1
                   │
                   ▼
   Osteoclast Differentiation, Fusion,
       Activation & Survival ──▶ BONE RESORPTION

1. RANKL (Receptor Activator of Nuclear Factor-κB Ligand):
   • A membrane-bound or cleaved soluble cytokine expressed by osteoblasts, osteocytes, and activated T- and B-lymphocytes.
   • Binds to its specific cognate transmembrane receptor, RANK, located on the surface of osteoclast progenitor monocytes and mature osteoclasts.
2. RANK (Receptor):
   • Binding of RANKL to RANK recruits intracellular adapter proteins, primarily TRAF6 (TNF Receptor-Associated Factor 6).
   • TRAF6 triggers downstream phosphorylation of the NF-κB pathway and Mitogen-Activated Protein Kinases (MAPKs: p38, JNK, ERK).
   • This induces the expression and auto-amplification of NFATc1 (Nuclear Factor of Activated T-cells c1), the master transcription factor required for osteoclast precursor fusion into multinucleated cells, activation of the ruffled border, and expression of TRAP and Cathepsin K.
3. OPG (Osteoprotegerin):
   • A soluble, circulating glycoprotein secreted by osteoblasts and marrow stromal cells.
   • Functions as a physiological decoy receptor that binds RANKL with high affinity, physically preventing RANKL from docking to its receptor RANK.
   • Consequently, OPG terminates osteoclastogenesis and induces apoptosis in mature osteoclasts, acting as a natural brake on bone resorption.

Clinical and Pathological Signalling

• The ratio of RANKL to OPG determines the rate of bone resorption. When the RANKL/OPG ratio increases, bone resorption accelerates; when OPG levels exceed RANKL, bone mass is preserved or increased.
• In Periodontitis and Periapical Pathoses: Bacterial lipopolysaccharide (LPS) activates local immune and stromal cells, inducing massive secretion of pro-inflammatory mediators (IL-1β, TNF-α, IL-6, and PGE₂). These cytokines dramatically upregulate RANKL while downregulating OPG, driving extensive alveolar bone destruction.
• Denosumab: A fully human monoclonal antibody (IgG₂) used in osteoporosis and oncology that specifically binds and neutralizes human RANKL. It functions pharmacologically as a synthetic, high-potency mimic of OPG, halting osteoclastogenesis.

---